David Dorward; Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID)Amid chronic under-investments in new antibacterial weapons, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative antibiotic now entering early clinical development. The compound BAL2420 targets LptA, part of the lipopolysaccharide transport bridge that Gram negative bacteria rely on to build their outer membrane.
Tag Archive for: Basilea
Swiss anti-infectives specialist Basilea Pharmaceutica has entered a research collaboration with U.S.-based Prokaryotics to develop a novel broad-spectrum antifungal aimed at treating severe invasive fungal infections, the companies announced on January 7th 2026.
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.